Next |
home / stock / msclf / msclf message board
Subject | By | Source | When |
---|---|---|---|
50m cash raised. Something brewing! | Oloo | investorshub | 04/20/2023 12:55:04 AM |
News on the go ! | Oloo | investorshub | 04/14/2022 2:28:13 PM |
On the way for a lead candidate: | Oloo | investorshub | 03/31/2022 4:53:10 PM |
Awesome thing coming soon ! | Oloo | investorshub | 12/14/2021 3:09:15 PM |
Effective Dec. 10,2021 ICOTF will change to MSCLF. | Renee | investorshub | 12/09/2021 3:04:03 PM |
As soon as FINRA posts the official ticker | Renee | investorshub | 08/18/2021 3:06:36 PM |
New ticker - MSCL - I use TD | Dapper1 | investorshub | 08/18/2021 2:41:17 PM |
$ICOTF: effective Aug. 18,2021 Ico Therapeutics Inc. will | Renee | investorshub | 08/17/2021 11:50:03 AM |
Newsfile Corp. | Dapper1 | investorshub | 07/13/2021 1:29:29 AM |
Wait for the next press release. We will | Oloo | investorshub | 03/25/2021 6:14:12 PM |
Voting No on this deal is crucial. Ico | boston79 | investorshub | 03/24/2021 4:28:51 PM |
Easy $1.00 thats only $152 million market cap, | boston79 | investorshub | 03/03/2021 3:02:54 PM |
Hello. Whats everyones price per share target here, | J_Dean | investorshub | 03/02/2021 9:11:23 PM |
CB-DT run imminent. Ico is a covid play | boston79 | investorshub | 02/24/2021 5:50:51 PM |
https://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15; | boston79 | investorshub | 02/19/2021 2:53:04 AM |
Someones front loading milllions of shares. Could be | boston79 | investorshub | 02/18/2021 3:57:42 PM |
Ya its a covid play now. This stock | boston79 | investorshub | 02/18/2021 2:21:11 PM |
Something going on! | Oloo | investorshub | 02/14/2021 9:32:32 PM |
It's here WoW | Mikefbi | investorshub | 01/25/2021 2:52:31 PM |
Acceleration event in the dec 1. Filing indicates | boston79 | investorshub | 12/08/2020 12:22:40 PM |
News, Short Squeeze, Breakout and More Instantly...
iCo Therapeutics Company Name:
MSCLF Stock Symbol:
OTCMKTS Market:
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSC...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of...
- Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 - On track to initiate Phase 1 first-in-human clinical trials mid-2024 - Cash balance of $33.2 million at March 31, 2024 - Invited to present at PPMD 30 th annual conference to be held J...